A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents
Free accessResearch articleFirst published online July, 2015
A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents
Cobicistat (COBI) is an alternative pharmacoenhancer to ritonavir. A fixed-dose combination (FDC) tablet containing atazanavir (ATV) and COBI has been developed for the treatment of HIV-1-infected patients.
Methods
This open-label, single-centre, single-dose, crossover study, randomized 64 healthy subjects to one of eight treatment sequences. Under light meal conditions, maximum plasma concentration (Cmax), area under the plasma concentration–time curve (AUC) to infinity (AUCINF) and AUC to the last measurable concentration (AUC0–T) for ATV and COBI administered as an FDC of ATV/ COBI (300/150 mg) were compared to those following administration as separate agents given together; bio-equivalence was concluded if the 90% CIs of the geometric mean ratios fell within the predetermined range of 0.80, 1.25. ATV and COBI pharmacokinetic parameters following administration as the FDC or as separate agents were also compared under fasted conditions. The effect of food (light and high-fat meals) on the pharmacokinetics of ATV and COBI for the FDC was also assessed.
Results
ATV and COBI administered in an FDC tablet were bioequivalent to the individual agents when given with a light meal. Under fasted conditions, pharmacokinetic parameters for ATV and COBI were similar for the individual components and the FDC. For the FDC, systemic exposure to ATV increased with a light meal compared to fasted conditions, and ATV concentration 24 h post-dose was similar with a light meal compared with a high-fat meal.
Conclusions
ATV/COBI (300/150 mg) FDC tablet was bio-equivalent to coadministration as separate agents with a light meal in healthy subjects. Clinicaltrials.gov identifier NCT01837719.
LichterfeldM., WohrmannA., SchmeisserN.Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.Eur J Med Res2003; 8: 56–60.
4.
ZeldinR.K., PetruschkeR.A.Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.J Antimicrob Chemother2004; 53: 4–9.
5.
FoisyM.M., YakiwchukE.M., HughesC.A.Induction effects of ritonavir: implications for drug interactions.Ann Pharmacother2008; 42: 1048–1059.
6.
JosephsonF.Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition.J Intern Med2010; 268: 530–539.
7.
AnnaertP., YeZ.W., StiegerB., AugustijnsP.Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Xenobiotica2010; 40: 163–176.
8.
LepistE.I., ZhangX., HaoJ.Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.Kidney Int2014; 86: 350–357.
9.
MarzoliniC., MuellerR., Li-BlatterX., BattegayM., SeeligA.The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.Mol Pharm2013; 10: 2340–2349.
DeeksE.D.Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.Drugs2014; 74: 195–206.
12.
MathiasA.A., GermanP., MurrayB.P.Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.Clin Pharmacol Ther2010; 87: 322–329.
13.
RamanathanS., WarrenD., WeiL., KearneyB.P.Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir.49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 12–15 September 2009, San Francisco, CA, USA. Poster A1-1301.
14.
ElionR., CohenC., GatheJ.Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.AIDS2011; 25: 1881–1886.
15.
GallantJ.E., KoenigE., Andrade-VillanuevaJ.Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.J Infect Dis2013; 208: 32–39.
SimonianH.P., VoL., DomaS., FisherR.S., ParkmanH.P.Regional postprandial differences in pH within the stomach and gastroesophageal junction.Dig Dis Sci2005; 50: 2276–2285.
20.
ZhangD., ChandoT.J., EverettD.W., PattenC.J., DehalS.S., HumphreysW.G.In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.Drug Metab Dispos2005; 33: 1729–1739.
21.
BangsbergD.R., RaglandK., MonkA., DeeksS.G.A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.AIDS2010; 24: 2835–2840.
22.
HodderS.L., MounzerK., DejesusE.Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.AIDS Patient Care STDS2010; 24: 87–96.
